Over the past decade, the survival rate of infants with congenital dia
phragmatic hernia (CDH) treated in the intensive care unit of the Roya
l Children's Hospital, Melbourne, has remained unchanged at 56% +/- 6%
. Newer forms of treatment, such as extracorporeal membrane oxygenatio
n (ECMO), high-frequency oscillation, and surfactant and nitric oxide
therapy, are now available. The exact role of these therapies in the m
anagement of infants with CDH has not been determined. This study exam
ines five clinical parameters derived from an infant's best preoperati
ve ventilatory and blood gas data in the first 24 hours of life. One h
undred twenty-five CDH infants were admitted to the intensive care uni
t between January 1, 1981 and December 31, 1991. Criteria for inclusio
n in the study were (1) CDH diagnosed within 6 hours of delivery, (2)
ventilation before repair, and (3) no associated lethal congenital abn
ormality. Of the 90 cases studied in detail, there were 38 deaths (42%
mortality rate). All five parameters were analyzed by receiver operat
ing curve analysis to determine the optimum value of each parameter in
predicting survival. An oxygenation index (MAP x Fio(2)/Pao(2)) of le
ss than 0.08 predicted a 94% chance of survival, with a sensitivity of
96% and a specificity of 95%. Similarly, a modified ventilation index
(PIP x RR x CO2/1,000) of less than 40 predicted a 91% chance of surv
ival, with a sensitivity of 94% and a specificity of 86%. By stratifyi
ng each criterion according to outcome, three groups of infants were i
dentified according to their response to conventional therapy. There i
s a large group of infants that can be expected to survive with conven
tional therapy and are likely to have minimal pulmonary hypoplasia. A
second group can be expected to die with use of conventional therapy;
this group may well represent infants with severe pulmonary hypoplasia
who are unlikely to benefit from therapies designed to combat pulmona
ry hypertension or minimize lung barotrauma. Between these two groups
is a small group of infants whose outcome from conventional therapy is
less predictable. We believe that this group may represent infants wi
th significant pulmonary hypertension and moderate pulmonary hypoplasi
a. These patients may benefit from newer therapies that treat pulmonar
y hypertension and minimize lung injury. Copyright (C) 1994 by W.B. Sa
unders Company